FOLD
Amicus Therapeutics Inc

6,383
Mkt Cap
$4.51B
Volume
1,155.00
52W High
$14.39
52W Low
$5.51
PE Ratio
-162.19
FOLD Fundamentals
Price
$14.37
Prev Close
$14.37
Open
$14.37
50D MA
$14.31
Beta
0.83
Avg. Volume
5.8M
EPS (Annual)
-$0.0879
P/B
16.29
Rev/Employee
$1.24M
$4,539.93
Loading...
Loading...
News
all
press releases
Amicus Therapeutics (NASDAQ:FOLD) Reaches New 12-Month High - Time to Buy?
Amicus Therapeutics (NASDAQ:FOLD) Hits New 12-Month High - Still a Buy...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Amicus Therapeutics (NASDAQ:FOLD) CEO Bradley Campbell Sells 22,500 Shares
Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) CEO Bradley Campbell sold 22,500 shares of the business's stock in a transaction on Monday, March 2nd. The shares were sold at an average...
MarketBeat·8d ago
News Placeholder
Bradley Campbell Sells 22,500 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock
Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) CEO Bradley Campbell sold 22,500 shares of the firm's stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an...
MarketBeat·8d ago
News Placeholder
JPMorgan Chase & Co. Has $16.68 Million Stock Position in Amicus Therapeutics, Inc. $FOLD
JPMorgan Chase & Co. reduced its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 4.3% in the 3rd quarter, according to the company in its most recent 13F filing with the...
MarketBeat·9d ago
News Placeholder
Vanguard Group Inc. Buys 126,441 Shares of Amicus Therapeutics, Inc. $FOLD
Vanguard Group Inc. lifted its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 0.4% in the third quarter, according to the company in its most recent disclosure with the Securities...
MarketBeat·11d ago
News Placeholder
William Blair Investment Management LLC Buys 1,107,083 Shares of Amicus Therapeutics, Inc. $FOLD
William Blair Investment Management LLC increased its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 7.6% during the third quarter, according to the company in its...
MarketBeat·12d ago
News Placeholder
Fox Run Management L.L.C. Takes $553,000 Position in Amicus Therapeutics, Inc. $FOLD
Fox Run Management L.L.C. acquired a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The fund...
MarketBeat·12d ago
News Placeholder
Primecap Management Co. CA Sells 128,200 Shares of Amicus Therapeutics, Inc. $FOLD
Primecap Management Co. CA cut its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 16.1% during the third quarter, according to its most recent 13F filing with the Securities and...
MarketBeat·13d ago
News Placeholder
BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market
BioMarin beats Q4 earnings estimates as Voxzogo drives year-over-year revenue growth. The company decides to voluntarily withdraw its hemophilia gene therapy.
Zacks·17d ago
News Placeholder
Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues
FOLD's Q4 earnings miss, but revenues beat estimates on strong Galafold and Pombiliti sales. The company is set to be acquired by BioMarin for $4.8 billion.
Zacks·18d ago
<
1
2
...
>

Latest FOLD News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.